Veradermics (MANE) Stock Price, News & Analysis

Company Overview

Veradermics is a clinical-stage biopharmaceutical company focused on developing treatments for hair loss. Its lead candidate, VDPHL01, is an investigational oral formulation of minoxidil being studied for androgenetic alopecia, commonly known as male- or female-pattern hair loss. The company has described the treatment as designed for once-daily use.

VDPHL01 remains under clinical investigation and is not an approved treatment. Veradermics is led by founder and Chief Executive Officer Reid Waldman, a physician specializing in dermatology.

Key Stats

• Today's Range: $146.73 to $156.63
• 50-Day Range: $97.70 to $156.11
• 52-Week Range: $32.00 to $156.63
• Volume: 703,747 shs
• Average Volume: 641,830 shs
• Market Capitalization: $6.52 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $174.57
• Consensus Rating: Moderate Buy

Veradermics Stock Analysis - MarketRank™

Veradermics scored higher than 44% of companies evaluated by MarketBeat, and ranked 530th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Veradermics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Veradermics has a consensus price target of $174.57, representing about 11.8% upside from its current price of $156.11.

Amount of Analyst Coverage

Veradermics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Veradermics are expected to decrease in the coming year, from ($2.87) to ($3.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Veradermics is -82.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Veradermics is -82.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.11% of the float of Veradermics has been sold short.

Short Interest Ratio / Days to Cover

Veradermics has a short interest ratio ("days to cover") of 5.06.

Change versus previous month

Short interest in Veradermics has recently decreased by 8.36%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Veradermics does not currently pay a dividend.

Dividend Growth

Veradermics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.93

News Sentiment

Veradermics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Veradermics this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for MANE on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Veradermics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Veradermics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $103,120,220.00 in company stock.

Percentage Held by Institutions

Veradermics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 11/10/2026
• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:MANE
• CIK: 1827635
• Web: www.veradermics.com
• Phone: (228) 372-3376
• Fax: N/A
• Employees: 21
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Veradermics: $174.57
• High Price Target: $204.00
• Low Price Target: $135.00
• Potential Upside/Downside: +11.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 70.53
• Quick Ratio: 70.53

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 41,780,000
• Free Float: N/A
• Market Cap: $6.52 billion
• Optionable: Optionable
• Beta: N/A